Cargando…

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis

OBJECTIVES: Osteoporosis is a rapidly rising cause of concern for elderly patients. Various classes of drugs are available in the market. Bisphosphonates are considered as a first-line therapy for the prevention and treatment. Denosumab is an antiresorptive agent which is a RANK ligand inhibitor. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benjamin, Biju, Benjamin, Mridula Ambwani, Swe, Myint, Sugathan, Sandheep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Osteoporosis 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372735/ https://www.ncbi.nlm.nih.gov/pubmed/30775470 http://dx.doi.org/10.1016/j.afos.2016.03.003

Ejemplares similares

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
por: Cotté, François-Emery, et al.
Publicado: (2011)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study
por: Marocco, Chiara, et al.
Publicado: (2021)

Socio demographic and lifestyle factors of metabolic syndrome among adult rural indigenous Malaysian population from Perak State, Malaysia
por: Sugathan, Sandheep, et al.
Publicado: (2021)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
por: Asche, C., et al.
Publicado: (2009)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a ‘real-life’ study
por: Fraser, T. R., et al.
Publicado: (2019)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
por: Karlsson, L., et al.
Publicado: (2015)

The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial
por: Moore, Amelia E., et al.
Publicado: (2023)

The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women
por: Rouach, Vanessa, et al.
Publicado: (2018)

Quality of life in post-menopausal osteoporosis
por: Bianchi, Maria Luisa, et al.
Publicado: (2005)

Oral Therapeutics Post Menopausal Osteoporosis
por: Schroeder, Ryan J, et al.
Publicado: (2023)

Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis–Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage
por: Martínez-Reina, Javier, et al.
Publicado: (2021)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
por: Tsuchiya, Koki, et al.
Publicado: (2021)

Differences between the bisphosphonates for the prevention and treatment of osteoporosis
por: Grey, Andrew, et al.
Publicado: (2006)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

POST-MENOPAUSAL OSTEOPOROSIS: Has it been medicalized?
por: Hogg, C. Alison
Publicado: (1997)

T cells and post menopausal osteoporosis in murine models
por: Pacifici, Roberto
Publicado: (2007)

Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
por: Sydlik, Carmen, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

Alopecia areata after denosumab treatment for osteoporosis
por: Lyakhovitsky, Anna, et al.
Publicado: (2016)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i4sd9vhnv96nore5sn1fc305rj